Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL

TO THE EDITOR: The anti-CD20 monoclonal antibody rituximab, together with anthracycline, in hepatitis B surface antigen (HBsAg) healthy carriers affected by non-Hodgkin lymphoma (NHL) increases hepatitis B virus (HBV) reactivation risk.[1][1] Oral primary antiviral prophylaxis (PAVP) is a common